All News

In recent years, pharmacists have increasingly become recognized as essential contributors to patient care and community health.

Guidance on the use of basal insulins (BI) and insulin pens to enable pharmacists to answer questions regarding the safe and effective use of BI for the management of diabetes.

Patients now have multiple options, including continuous therapy with BTK inhibitors and fixed-duration therapy with venetoclax-based regimens.

September is National Recovery Month, so Pharmacy Times interviewed Rich Dion, PharmD, of Wolters Kluwer, Health, on the critical role of the hospital pharmacist in ongoing efforts to fight the opioid epidemic.

Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.

Dr. Jason Liu and his colleagues hoped to assess the use of maintenance durvalumab based on patient and physician characteristics among individuals with stage 3 NSCLC in the United States.

Jason Ausili, PharmD, the Chief Clinical Officer of FDS Amplicare, discusses the impact on community pharmacies and patients of the recent announcement by the HHS regarding the amendment to the COVID-19 PREP Act.

Survey participants saw potential for immunotherapy use in earlier stages of several diseases, including melanoma, lung cancer, and bladder or urothelial cancer.

Pharmacy health-system managers should understand the key components of the drug quality and security act.

Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines.

iImplementation science is an emerging concept examining the development of services in a way that not only helps ensure their initial execution but also their sustainability over time.

New research results show that patients with mild coronavirus produce antibodies that are able neutralize the infection.

Customers vaccinated at any Rite Aid location can supplement their paper vaccination card with a verified digital version that can be accessed on their mobile device.

The regimen with chemotherapy continues to show longer rates at 9 months compared with 4.9 months for chemotherapy and the placebo.

In the MAGNOLIA trial, the median duration of response was not reached at the median follow-up time of 8.3 months, with 85% of responders still in remission at 12 months.

Immediate and second- and third-degree family members can benefit from colonoscopy screenings, new research results show.

But the good news is treatments can be tailored for patients with the chronic behavioral condition.

Stereotactic ablative radiotherapy has similar overall and progression-free survival rates.

Among patients treated with the combination of nivolumab and ipilimumab, 23% were alive at 3 years, compared to 15% of patients treated with chemotherapy.

Cabozantinib (Cabometyx) was approved in 2016 for patients who have advanced renal cell carcinoma and who received prior anti-angiogenic therapy.

Research results show a possible link between herpesviruses and neurodegenerative diseases, such as Alzheimer disease, ALS, and glaucoma.

There are several types of sleep apnea, but the most common is obstructive sleep apnea.

The investigators noted that heart attacks are often caused by the rupturing of vulnerable plaques, defined as plaques with a large lipid core with a thin fibrous cap that serves as a wall or barrier around the plaque to keep it intact.

Pharmacists should stay knowledgeable about recommendations and evidence related to therapies.

Beyond the benefits to the pharmacist profession, granting provider status to pharmacists addresses the larger societal problem of growing physician shortages.

In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.

Individuals who had depression or stress in a hospital in Mexico were also 4.5 and 3.18 times more likely, respectively, to experience delays in treatment.